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Background/aim: The differences in molecular mechanisms during a stable period and the changes in the inflammatory responses
during exacerbations between distinct severe asthma phenotypes remain unclear. In this study, we aimed to characterize stable and
exacerbation period serum cytokine and periostin levels of 5 different predefined severe asthma phenotypes with real-life data. Changes
in the viral infection-induced exacerbations were also analyzed.
Materials and methods: Serum levels of 8 cytokines and periostin were measured from the sera obtained from the adult patients with
five different severe asthma phenotypes based on the presence/absence of aeroallergen sensitivity, peripheral eosinophilia and chronic
rhinosinusitis with nasal polyposis (CRSwNP) during stable and exacerbation periods, and from the matched controls.
Results: Serum IL-13, IL-25, TSLP, and periostin levels were similar between the patient and the control groups during stable and
exacerbation periods. Serum IL-25 and TSLP levels, and peripheral eosinophil count and periostin level showed a strong correlation.
Stable period periostin levels were significantly higher in eosinophilic patients, and eosinophilic patients without long-term systemic
steroid therapy had higher IL-13 levels. Compared to stable period, exacerbation period serum periostin levels found significantly lower
[5853 (2309–8427) pg/mL vs. 4479 (2766–6495) pg/mL; p = 0.05] and periostin levels were much lower in viral infection-induced
exacerbations [2913 (893–4770) pg/mL vs. 7094 (4782–9596) pg/mL; p = 0.022].
Conclusion: Our study showed that serum periostin levels were decreased in viral infection-induced exacerbations and increased in
the presence of eosinophilia independent from atopy and it can help to differentiate eosinophilia even if the patient is under long-term
systemic steroid therapy. Also, serum IL-13 levels may reflect peripheral eosinophilia in patients without long-term systemic steroid use.
Key words: Severe asthma, asthma phenotypes, eosinophilic asthma, allergic asthma, nonallergic asthma, type-2 high asthma

1. Introduction
International ERS/ATS guidelines on the definition of
severe asthma define severe asthma as “asthma which
requires treatment with high dose inhaled corticosteroids
plus a second controller (and/or systemic corticosteroids)
to prevent it from becoming ‘uncontrolled’ or which
remains ‘uncontrolled’ despite this therapy” [1]. Severe
asthma constitutes the majority of the health-related
expenses and the management of the disease remains
challenging [1,2].
Severe asthma is a heterogeneous condition that has
different phenotypes with distinct clinical characteristics
and different endotypes with distinct underlying
pathophysiological mechanisms [3]. The current
personalized severe asthma treatment protocols involve
targeted biological therapies based on the phenotypes and
biological markers [4,5]. Hence cheap, feasible, and easy-

to-access biological markers that may help to identify the
asthma phenotypes and potential treatment options for
these phenotypes are needed. In our clinical practice, we
identify asthma phenotypes according to the peripheral
eosinophilia and/or atopy status of the patients [6,7]. This
classification is helpful in type-2 (T2)-high and T2-low
asthma differentiation and T2 targeted biological agent
choice.
The differences in molecular mechanisms between the
phenotypes remain unclear and also phenotypes may not be
always adequate to reveal the underlying pathophysiological
processes, which are called endotypes. Two main endotypes
of severe asthma are currently acknowledged: T2-high
asthma, in which there is a significant T2 inflammation
in airways; and T2-low asthma, where T2 inflammation
is not significant [8–10]. T2-high asthma is typically
characterized by eosinophilic airway inflammation of
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various degrees. Due to allergen-independent signaling
processes, allergic mediators may not always be evident
in T2-high asthma [8]. Downstream pathways are much
better clarified in the T2-high endotype which is mainly
regulated by IL-4, IL-5, and IL-13 producing Th2 and type2 innate lymphoid (ILC2) cells [11].
Patients with severe asthma experience frequent
exacerbations and viral infections are among the most
common causes [12]. It is known that viral infections
increase the expression of airway epithelium-born
cytokines such as IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP) and stimulate ILC2 responses.
T1 and/or T2 inflammatory response profiles may also
emerge depending on the virus type [12]. The changes in
the inflammatory response in different asthma phenotypes,
particularly in viral infection-induced exacerbation
periods, remain unclear. Therefore, in this study, we aimed
to characterize stable and exacerbation period peripheral
blood cytokine and periostin levels of 5 different predefined
severe asthma phenotypes with real-life data. Changes
in the viral infection-induced exacerbations were also
analyzed.
2. Materials and methods
2.1. Subjects and severe asthma phenotypes
This prospective observational study was conducted
in Erciyes University Division of Allergy and Clinical
Immunology, Turkey, between November 2018 and
October 2019. Adult patients who were under followup in our clinic for at least 6 months with the diagnosis
of severe asthma [1] and matched control subjects were
included. Inclusion and exclusion criteria are listed in
Table 1. Written informed consent was obtained from
all participants. The study was approved by the research
and ethics committees of Erciyes University (2018/289).
The study was registered to the NIH trial registry with the
identifier NCT03563521.
We defined five different severe asthma phenotypes
based on the presence/absence of aeroallergen sensitivity
(at least one perennial aeroallergen skin prick test positivity
of the 13 common aeroallergens), peripheral eosinophilia
and chronic rhinosinusitis with nasal polyposis (CRSwNP)
in accordance with our previously published asthma
phenotyping system, which is routinely used in our clinical
practice [6] (Table 2). In order to better reflect the real-life
data and make the subgroup analysis possible, patients
who were under long-term systemic steroid treatment
were also included in the study. Matched controlled group
consisted of healthy subjects without asthma, aeroallergen
sensitivity, and peripheral eosinophilia.
2.2. Sample collection and measurements
The patients were evaluated during stable and also, if
occurred, during the exacerbation periods. For the stable

period data, pulmonary function data, ACT score, and
venous blood samples of the patients were collected
and separated at the same visit. Acute and progressive
worsening of asthmatic symptoms which require the use of
systemic corticosteroids or an increase in the use of daily
maintenance systemic corticosteroids to prevent a serious
outcome accepted as acute exacerbation, and venous blood
samples were collected and separated at the same visit.
Differential white blood cell count was carried out
from all venous blood samples at the same visit using a
Beckman Coulter Automated Complete Blood Count
Analyzer (Beckman Coulter Inc., Fullerton, Miami,
FL). Serum samples were frozen at –70 °C until the day
of analysis and thawed once before analysis. The serum
concentrations of 8 cytokines and periostin were measured
with a sandwich enzyme-linked immunosorbent assay
system [IL-4 (EK0404), IL-5 (EK0407), IL-10 (EK0416),
IL-13 (EK0424), IL-17 (EK0430), IL-17E/25 (EK0793), IL33 (EK0929), TSLP (EK0958), periostin/OSF2 (EK0985)
ELISA Kit PicoKine™ (Boster Biological Technology,
Pleasanton CA, USA)] according to the manufacturer
instructions.
2.3. Upper airway viral screening with multiplex PCR
In every acute exacerbation, possible triggers were
evaluated. If viral upper respiratory tract infection was
suspected as the etiology by the clinician, a nasopharyngeal
flocked swab was obtained and cultivated in a viral liquid
medium. Clinical samples were analyzed using the Fasttrack Respiratory Pathogen assay (Fast-track Diagnostics,
Luxembourg) on the very same day. This panel was used in
a multiplex PCR assay that detects respiratory pathogens,
including human respiratory syncytial viruses A/B,
influenza A virus, influenza A (H1N1) virus, influenza
B virus, human adenovirus, human parainfluenza virus
types 1–4, human rhinovirus, human enterovirus,
human metapneumovirus A/B, human bocavirus, human
coronavirus types OC43, 229E, NL63, and HKU1, human
parechovirus, and Mycoplasma pneumonia.
2.4. Statistical analysis
Data were analyzed using SPSS software version 17 (SPSS
Inc, Chicago, Illinois, USA). Intergroup comparisons of
numerical variables were made using one-way ANOVA
or Kruskal-Wallis test according to the distribution
and intergroup comparisons of categorical variables
were made using chi-square test. Protein concentration
(cytokines and periostin) data were expressed as mean
[range] and a comparison of cytokine and periostin
levels during stable and exacerbation periods were
performed with the Wilcoxon test. P-values of less than
0.05 were considered statistically significant. Post-hoc
power analysis was carried out to evaluate the minimum
sample size required to achieve a power of 80% at a 5%
alpha level.
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3. Results
Ninety-one volunteers (76 patient group, 15 control
group) were included in the study (Table 2). The mean age
was 45.5 ± 10.4 and 77 (85%) of all volunteers were female.
In the patient group, the mean peripheral eosinophil count
was 316.7 (130–420) cells/mL, 36 (48%) had atopy and
19 (25%) were under long-term systemic steroid therapy
(Table 3).
There was no significant difference in gender, age,
FEV1, and ACT scores distribution among the defined
severe asthma phenotypes. The control group and the
patient group had similar age and gender distribution.
Systemic steroid use was significantly higher in phenotype
4 (Table 3).
3.1. Stable period measurements
In the patient group, IL-4 was detectable in 1 patient,
IL-5 in 1 patient, IL-10 in 2 patients, IL-17 in 1 patient,
and IL-33 in 3 patients in the stable period. Therefore, no
further comparison was done with these cytokines. Mean
IL-13 level was 13.1 pg/mL (Figure 1A), IL-25 level was
194.2 pg/mL (Figure 1B), TSLP level was 105.2 pg/mL
(Figure 1C) and periostin level was 7194 pg/mL (Figure
1D) in the patient group (Table 4). Serum IL-13, IL25, TSLP, and periostin levels were similar between the

patient group and the control group (p = 0.095; 0.072;
0.221 and 0.696; respectively).
3.1.1. IL-13
Even though there was no significant difference in IL-13
levels between the control and the patient groups, when
phenotype 3 was compared with the control group, IL-13
levels were found significantly lower in this phenotype
[6.1 (0–5.2) pg/mL vs. 20.8 (0–29.9) pg/mL; p = 0.026]
(Table 4). There was no difference in IL-13 levels when
other asthma phenotypes were compared to the control
group.
In order to find the possible effect of systemic steroid
use on serum cytokine levels within different phenotypes,
patients with and without long-term systemic steroid
therapy were compared. We found significantly higher
IL-13 levels in atopic patients under systemic steroid
therapy and eosinophilic patients without systemic
steroid therapy (Table 5).
There was no correlation between ACT scores, FEV1
values, peripheral eosinophil counts, and IL-13 levels
during a stable period.
3.1.2. IL-25
Even though there was no difference in IL-25 levels
between the control and the patient groups, when

Table 1. Inclusion and exclusion criteria for the patients.
Inclusion criteria
1.

Diagnosis of severe asthma according to the International ERS/ATS guideline (1)

2.

Under follow-up for severe asthma for at least 6 months in our clinic

3.

Meets the defined phenotype criteria of the study

Exclusion criteria
1.

Under 18 years of age

2.

Smoking history in the last 1 year

3.

Under monoclonal antibody treatment for severe asthma or any other disease.

4.
Comorbidities: malignancy, collagen tissue disease, hyperthyroidism, cardiovascular diseases, type 2 diabetes, active liver
disease, acute kidney failure or any autoimmune disorder
5.

Solid organ transplantation

6.

Pregnancy

7.
Pulmonary diseases other than asthma: chronic obstructive pulmonary disease, bronchiectasia, interstitial lung diseases,
pulmonary thromboemboli
8.
a.
b.
c.

For the stable period assessment:
Asthma Control Test (ACT) < 16
Upper respiratory infection within the last 1 month
Exacerbation and/or systemic steroid treatment within the last 1 month

9.
d.

For the exacerbation period assessment:
Out of routine daily systemic steroid use before admission

10.

Atopy with only seasonal allergen sensitivity
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phenotype 2 was compared with the control group, IL25 levels were significantly lower in this phenotype [0 vs.
160.6 (0–220.6) pg/mL; p = 0.02] (Table 4). There was
no difference in IL-25 levels when other phenotypes
were compared to the control group. There was a strong
correlation between IL-25 levels and TSLP levels in
stable period (r = 0.963; p < 0.001) (Figure 2), no such
correlation was found with the other cytokines. In
patients without systemic steroid therapy, there was an
almost-significant difference between the eosinophilic
and noneosinophilic groups (Table 5).
3.1.3. TSLP
TSLP levels were significantly lower in phenotype 2
compared to the control group [0 vs. 80.4 (0–169) pg/
mL; p = 0.017] (Table 4). There was no difference in TSLP
levels when other asthma phenotypes were compared to
the control group. In patients under systemic steroid
therapy, the difference in TSLP levels between the
eosinophilic and noneosinophilic groups was significant
[0 vs. 149 (0–16) pg/mL; p = 0.025] (Table 5).

3.1.4. Periostin
Periostin levels were significantly higher in phenotype 1 and
phenotype 4 when compared to phenotype 5 [8067 (7028–
9777) pg/mL vs. 5830 (3953–7437) pg/mL; p = 0.015 and
8137 (6315–9620) pg/mL vs. 5830 (3953–7437) pg/mL; p =
0.006, respectively] (Table 4). Stable period periostin levels
were also significantly higher in eosinophilic patients [7783
(6660–9523) pg/mL vs. 6242 (3783–8267) pg/mL; p = 0.009]
(Table 5). This difference was more prominent in patients
without systemic steroid therapy. Peripheral eosinophil
count was significantly correlated with the stable period
periostin levels (r = 0.351, p = 0.004) (Figure 3). Presence of
atopy had no significant effect on periostin levels.
3.2. Exacerbation period measurements
During the study, 23 patients had asthma exacerbation
and serum samples were collected. Six of those had atopic
eosinophilic, 5 had nonatopic eosinophilic, 7 had atopic
noneosinophilic, 3 had CRSwNP eosinophilic and 2 had
nonatopic noneosinophilic phenotype. The presence of
systemic steroid therapy, atopy, or eosinophilia had no
effect on exacerbation frequency.

Table 2. Definition criteria of the five different severe asthma phenotypes.
Phenotypes

Definition criteria

# of volunteers

Phenotype 1: Atopic, eosinophilic severe
asthma (A-E)§

· At least 1 perennial aeroallergen sensitivity
· Peripheral eosinophil count > 300 cells/mL in at least 2 blood
samples 1 month apart¥

11

· No aeroallergen sensitivity
Phenotype 2: Nonatopic, eosinophilic severe
· Peripheral eosinophil count > 300 cells/mL in at least 2 blood
asthma (NA-E)
samples 1 month apart¥

18

Phenotype 3: Atopic, noneosinophilic
severe asthma (A-NE)§

· At least 1 perennial aeroallergen sensitivity
· Peripheral eosinophil count < 150 cells/mL in at least 2 blood
samples 1 month apart during steroid-naive period

16

Phenotype 4: Eosinophilic severe asthma
with comorbid chronic rhinosinusitis with
nasal polyposis (E-CRSwNP)§

· Chronic rhinosinusitis and nasal polyposis diagnosis by
physical examination, nasal endoscopy or PNCT
· NERD may accompany
· Aeroallergen sensitivity may accompany
· Peripheral eosinophil count > 300 cells/mL in at least 2 blood
samples 1 month apart¥

18

Phenotype 5: Nonatopic, noneosinophilic
severe asthma (NA-NE)

· No aeroallergen sensitivity
· Peripheral eosinophil count < 150 cells/mL in at least 2 blood
samples 1 month apart during steroid-naive period

13

Control group

· Healthy subjects without proven asthma, aeroallergen
sensitivity and peripheral eosinophilia

15

PNCT: Paranasal sinus computed tomography; NERD: Nonsteroidal antiinflammatory drug exacerbated respiratory disease
§ If pollen sensitivity is present in addition to perennial allergen sensitivity, serum samples were collected out of the pollen season for
stable period measurements.
¥ In case of long-term systemic steroid treatment, inclusion criteria for blood eosinophil count were accepted as > 150 cells/mL.
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Figure 1. Stable period serum IL-13 (A), IL-25 (B), TSLP (C) and periostin (D) levels of five different severe asthma phenotypes and
the control group determined by ELISA.

10000

1000

100
Page 1

10

Peripheral eosinophil count (ccells/ml)

Serum IL-25 level (pg/mL)

1200

1000

800

600

Page 1
400

200

1
0

0

0

1

10

100

1000

10000

0

2000

4000

6000

8000

10000

Serum periostin level (pg/mL)

Serum TSLP level (pg/ml)

Figure 2. In stable period, serum levels of IL-25 and TSLP
showed a strong correlation (r = 0.963; p < 0.001).
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Figure 3. In stable period, serum periostin level and peripheral
eosinophil count showed a significant correlation (r = 0.351, p
= 0.004).

TÜRK et al. / Turk J Med Sci
Table 3. General characteristics of the phenotypes.

Patient group
n = 76

Phenotype 1
(A-E)
n = 11

Phenotype 2
(NA-E)
n = 18

Phenotype 3
(A-NE)
n = 16

Phenotype 4
(E-CRSwNP)
n = 18

Phenotype 5
(NA-NE)
n = 13

p

Female gender; n
(%)

66 (87)

9 (82)

15 (83)

14 (88)

16 (89)

12 (92)

0.93

Age (years); mean
± SD

45.6 ± 11.1

46 ± 11.7

47.4 ± 12.8

41 ± 11.9

48.1 ± 8.8

46.4 ± 9.9

0.466

Chronic
52 (70)
rhinosinusitis; n (%)

6 (60)

8 (44)

14 (93)

18 (100)

6 (46)

<0.001

Long-term systemic
19 (25)
steroid use; n (%)

1 (9)

3 (17)

2 (13)

13 (72)

0

<0.001

FEV1; mean % of
predicted ± SD

90.5 ± 20.1

84.9 ± 17

93.1 ± 27.1

95.3 ± 24.3

84.8 ± 15.7

93.3 ± 11.5

0.578

FEV1; mean cc
(IQR)

2451
(1860–2620)

2441
(1715–3020)

2384
(1830–2707)

2738
(2100–3370)

2197
(1645–2545)

2583
(2227–2572)

0.488

ACT; mean (IQR)

20.8 (20–23)

20.9 (20–23)

20.9 (20–23)

19 (18–22)

22 (20–24)

21.1 (20–22)

0.183

Peripheral
eosinophil count;
mean % (IQR)

3.7 (1.5–4.8)

6.2 (3.8–8.1)

5 (3.1–7.8)

1.8 (1.3–2.5)

4.8 (2.3–6)

1.26
(0.73–1.68)

<0.001

548 (295–920)

408 (270–552)

122 (90–150)

465.9 (240–580) 91.7 (50–132)

Peripheral
eosinophil count;
316 (130–420)
mean cells/mL (IQR)

<0.001

SD: standard deviation; FEV1: forced expiratory volume in 1 s; ACT: asthma control test; IQR: interquartile range

Table 4. Comparison of IL-13, IL-25, TSLP, and periostin levels in asthma phenotypes and control group.
Patient group Phenotype 1
n=76
(A-E)

Phenotype 2
(NA-E)

Phenotype 3 Phenotype 4 Phenotype 5
(A-NE)
(E-CRSwNP) (NA-NE)

Control
group

p*

IL-13; mean 13.1
pg/mL (IQR) (0–26.1)

15.3
(0–29.9)

17
(0–26.1)

6.1
(0–5.2)

12.9
(0–24.89)

15.7 (0–30.59)

20.8 (0–29.9)

0.215

IL-25; mean
194.2 (0)
pg/mL (IQR)

240.6
(0–466)

0

138
(0–133)

0

328.6
(0–32.03)

160.6
(0–220.6)

0.196

TSLP; mean
105.2 (0)
pg/mL (IQR)

107.3
(0–140)

0

73.8
(0–12)

0

218.2 (0–14.9)

80.4
(0–169)

0.353

Periostin;
7194
mean pg/mL
(5520–9385)
(IQR)

8067
(7028–9777)

7182
(5655–8328)

6703
8137
(3744–8478) (6315–9620)

5830
(3953–7437)

7217
(6422–9010)

0.041

*Comparison of all phenotypes and the control group (Kruskal Wallis test).
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Table 5. Effects of systemic steroid therapy, atopy and peripheral eosinophilia on stable period IL-13, IL-25, TSLP, and periostin levels.
Atopy

n = 76

With

Without

p

IL-13; mean
pg/mL (IQR)

19.2 (0–30)

5.9 (0–15.6)

0.033

IL-25; mean
pg/mL (IQR)

527.8 (0–408)

139.8 (0–402.3)

0.736

292 (0–290)

0

0.36

With long term
systemic steroid TSLP; mean
use n = 19
pg/mL (IQR)

Without long
term systemic
steroid use n
= 57

Peripheral eosinophilia
With

Without

p

n/a*

Periostin;
mean pg/mL
(IQR)

8284 (7749–9615) 6719 (3535–9153) 0.183

IL-13; mean
pg/mL (IQR)

7.2 (0–20.7)

17.2 (0–29.9)

0.019

17.2 (0–28)

8.6 (0–14.3)

0.034

IL-25; mean
pg/mL (IQR)

130.4 (0–185)

0

0.145

0

235.2 (0–58.7)

0.081

TSLP; mean
pg/mL (IQR)

63.1 (0–3)

0

0.347

0

149 (0–16)

0.025

Periostin;
mean pg/mL
(IQR)

7292 (6630–9440) 6877 (5301-8391) 0.311

8071 (7042-9518) 6153 (3770–7851) 0.007

* There was only 1 patient in the noneosinophilic group and no further comparison was done.

3.2.1. IL-13
There was no difference in IL-13 levels between asthma
phenotypes during exacerbations (Table 6). However, IL13 levels were significantly different between atopic and
nonatopic patients [12.5 (0–13.74) pg/mL vs. 1.1 (0–3.19)
pg/mL; p = 0.02]. No such difference was found for the
presence of eosinophilia or systemic steroid use.
3.2.2. IL-25
There was no difference in serum IL-25 levels between
asthma phenotypes during exacerbations. The presence
of systemic steroid therapy, atopy, or eosinophilia had
no effect on IL-25 levels. There was a strong correlation
between IL-25 and TSLP levels (r = 0.895, p < 0.001). No
such correlation was found with the other cytokines.
3.2.3. TSLP
There was no difference in serum TSLP levels between
asthma phenotypes during exacerbations. The presence
of systemic steroid therapy, atopy, or eosinophilia had no
effect on TSLP levels.
3.2.4. Periostin
There was no difference in serum periostin levels between
asthma phenotypes during exacerbations. The presence
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of systemic steroid therapy, atopy, or eosinophilia had no
effect on periostin levels.
3.3. Comparison of stable and exacerbation periods
When IL-13, IL-25, TSLP, and periostin levels during the
stable and exacerbation periods were compared, 23 patients
with exacerbation had significantly lower periostin levels
during the exacerbation period [5853 (2309–8427) pg/mL
vs. 4479 (2766–6495) pg/mL; p = 0.05] (Figure 4). No such
change was depicted with the other cytokines (Table 7).
All these 23 patients had increased peripheral eosinophil
counts during exacerbations [229 (120–280) cells/mL for
stable and 780 (130–490) cells/mL for exacerbation; p =
0.009]. Periostin levels and blood eosinophil counts were
also correlated during exacerbations (r = 0.454; p = 0.029).
3.4. Change in viral exacerbations
Thirteen patients had a nasopharyngeal mucosal swab
taken due to upper respiratory tract infection suspicion
during the exacerbation period. In 6 of these, viral etiology
was detected by multiplex PCR (2 RSV, 2 influenza A, 1
influenza B, and 1 rhinovirus). Periostin levels were
significantly lower in virus-positive group compared to
virus-negative group during exacerbation period [2913
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Figure 4. Serum periostin levels were compared between stable and exacerbation periods.

Table 6. Comparison of IL-13, IL-25, TSLP, and periostin levels between asthma phenotypes during exacerbations.
Patient group
n = 23

Phenotype 1
(A-E)

Phenotype 2
(NA-E)

Phenotype 3
(A-NE)

Phenotype 4
(E-CRSwNP)

Phenotype 5
(NA-NE)

p

IL-13; mean pg/
8.5 (0.11)
mL (IQR)

18.7
(0.44.7)

1.7
(0–4.3)

10.4
(1.5–19.8)

3.4 (0–10.1)

0

0.203

IL-25; mean pg/
300.9 (0–356)
mL (IQR)

871.4
(0.2179)

186.6
(0–466.5)

187
(0–387.5)

45 (0–135)

Page01

0.685

TSLP; mean pg/
100.9 (0)
mL (IQR)

349.2
(0–873)

0

71.7
(0–176.3)

0

0

0.328

Periostin; mean 4479
pg/mL (IQR)
(2766–6495)

3977
(1963–6290)

4231
(1161-7756)

4779
(3720–6137)

5191 (2766–9596) 4087 (385–7789) 0.926

Table 7. Comparison of cytokine levels during stable and exacerbation periods.
n = 23

Stable period

Exacerbation period

p

IL-13; mean pg/mL (IQR)

9.7 (0–26.5)

8.5 (0–11)

0.638

IL-25; mean pg/mL (IQR)

290.1 (0–575)

301 (0–356)

0.386

TSLP; mean pg/mL (IQR)

119.9 (0–63.8)

100.9 (0)

0.866

Periostin; mean pg/mL (IQR)

5853 (2309–8427)

4479 (2766–6495)

0.05
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(893–4770) pg/mL vs. 7094 (4782–9596) pg/mL; p =
0.022]. No such difference was present with the other
cytokines. A post hoc power analysis indicated low power
(power < 80%) to detect differences between the patient
and control group.
4. Discussion
In the present study, in 5 distinct clinic/inflammatory
severe asthma phenotypes which were defined based on
the presence or absence of atopy, peripheral eosinophilia,
and CRSwNP in the real-world settings, serum levels of
8 different cytokines and periostin were studied during
stable and exacerbation periods. Even though serum IL13, IL-25, TSLP, and periostin levels showed no significant
difference between the patient and control groups, each
serum protein showed a significant difference among
asthma phenotypes according to the presence of atopy,
eosinophilia, exacerbation, viral infection, or use of longterm systemic steroids.
Asthma is a heterogeneous disease which
includes different clinical phenotypes and distinct
pathophysiological endotypes. T2-high phenotype
constitutes approximately 50%–70% of all asthma patients
[5]. IL-4, IL-5, and IL-13 are the main cytokines involved
in T2 inflammation. In our study, only serum IL-13 showed
significance out of these three cytokines. IL-13 is a central
effector cytokine in asthma and the pivotal regulator in
IgE synthesis, goblet cell hyperplasia, airway remodeling,
mucus hypersecretion, and airway hyperresponsiveness
[13]. IL-13 is also a central inducer of periostin production
from airway epithelial cells [14]. Since the key mediator
role of IL-13 is evident in allergic inflammation,
measurement of IL-13 levels with direct or indirect
markers is important in the diagnosis and endotyping of
severe asthma. IL-13 can be measured in induced sputum;
however, sputum induction and interpretation are not
feasible in real-life. As in most the cytokines, a very little
amount of IL-13 passes to the bloodstream and usually is
very hard to depict in the serum. Since our study involves
severe asthma patients with possibly a more severe type2 inflammation and a higher amount of circulating
cytokines, we tried to measure IL-13 levels directly in
the serum. We found no significant difference in serum
IL-13 levels between the patient and the control groups.
When compared in pairs, IL-13 levels were significantly
lower in phenotype 3 in our study, in which none of the
patients were under long-term systemic steroid treatment.
We believe this finding is most likely due to the small
percentage of IL-13 positivity in phenotype 3, since IL-13
levels in phenotype 3 were found significantly lower even
than in phenotype 5 (nonatopic, noneosinophilic severe
asthma phenotype). IL-13 levels were also significantly
higher in atopic patients under long-term systemic steroid
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therapy and eosinophilic patients without systemic steroid
therapy. Eighteen of 19 patients under systemic steroid
therapy also had peripheral eosinophilia, and 13 were in
the phenotype 4 group. Therefore, we may suggest that
IL-13 levels may be affected by peripheral eosinophilia
rather than the presence of atopy. It was reported that
IL-13 can induce eosinophil activation, recruitment and
prolongs eosinophil survival [15]. IL-4 and IL-13 are both
potent inducers of VCAM-1 in endothelial cells, which
are important for the recruitment of eosinophils [13].
The relationship between serum IL-13 levels and atopiceosinophilic asthma has been reported in previous studies
[16–19]. Hussein et al. showed a higher serum IL-13 levels
in children with atopic asthma compared to the control
group and a correlation between serum IL-13 levels and
disease severity [17]. Peripheral eosinophil counts were
particularly high in this study and as for IL-13, peripheral
eosinophilia was also correlated with disease severity.
Kalinauskaite‐Zukauske et al. reported significantly
higher IL-13 levels in atopic asthma patients compared to
the control group and an increase in IL-13 levels after the
bronchial allergen challenge test with D. pteronyssinus [18].
Basal peripheral eosinophil counts were near twice the
control group in atopic asthmatic patients in this study. In
their clustering study using multidimensional endotyping
with different biomarkers and clinical phenotypes, Agache
et al. found that serum IL-13 is a reliable biomarker to
detect peripheral eosinophilia and, in another study, they
also showed that high eosinophilic moderate asthma
cluster had significantly increased serum IL-13 levels
[20, 21]. Apart from asthma, serum IL-13 levels are also
shown to increase in CRSwNP. In their study where serum
cytokine levels were compared in chronic rhinosinusitis
with nasal polyps and control group, Nabavi et al. reported
a significantly higher serum IL-13 level in CRSwNP group.
The authors also showed that IL-13 levels were not affected
by atopy status [22].
Allergens, toxic substances, and viral infections cause
the release of IL-25, IL-33, TSLP cytokines, the so-called
alarmins, from the airway epithelium and induce type-2
inflammation via ILC2 and Th2 cells in asthma [23]. IL-33
could not be detected in serum in our study. There was also
no difference in IL-25 and TSLP levels between the patient
and control groups. IL-25 and TSLP were significantly
correlated in both stable and exacerbation periods.
Their levels were also significantly lower in patients with
peripheral eosinophilia without long-term systemic
steroid therapy. In a previous study where serum levels
of 24 different cytokines and chemokines were studied in
severe asthmatic patients, IL-25 levels were also similar
in control and asthma groups [16]. In addition, TSLP
levels were also significantly higher in asthma groups. The
authors also stated that there was no difference in these
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two cytokines when controlled and uncontrolled asthma
patients were compared. In another study, where baseline
IL-25 and TSLP levels were similar between atopic
asthmatic patients and the control group, a significant
increase in these two cytokine levels was observed after
the bronchial inhaler challenge [18]. In our study, IL-25
and TSLP were not detected in the serum of phenotype
2 patients in which none of the patients were under longterm systemic steroid therapy. These two cytokines could
not be detected in phenotypes 2 and 4, where eosinophilia
is prominent, but had significant or almost-significantly
higher levels in phenotypes 1 and 3, where atopy is present
when compared to phenotype 2. Therefore, we may
speculate that the serum positivity of these cytokines may
be more valuable for demonstrating the presence of atopy.
Periostin is a matricellular protein broadly secreted
by many tissues including the airway epithelium,
musculoskeletal system, and gastrointestinal tract. It is
upregulated by type-2 cytokines like IL-4 and IL-13 and
correlates with other type-2 biomarkers such as FeNO,
sputum eosinophilia, blood eosinophilia, and total IgE [24,
25]. In concordance with our results, recent studies showed
that serum periostin measurement may be inadequate in
differentiating asthmatic and healthy subjects [14, 16, 25].
Serum periostin levels were reported to be higher even in
professional athletes compared to asthmatic patients [26].
Periostin is pronounced to be more useful in the evaluation
of response to monoclonal antibodies and systemic steroid
therapy, rather than asthma diagnosis. In addition, it may
also be used in differentiating asthma subtypes where
airway eosinophilia is present [14, 27]. Serum periostin
levels were elevated in asthmatics with CRSwNP and
serum periostin could distinguish these patients from
asthmatics without any comorbidities [28]. In our study,
we found that periostin levels were strongly correlated
with peripheral eosinophilia levels and could be helpful in
differentiating eosinophilia despite systemic steroid use.
Agache et al. also showed that serum periostin is one of
the best predictors of blood eosinophilia [20]. In addition
to its inadequacy for asthma diagnosis, there is also very
limited data on its use during exacerbations. Semprini et
al. recorded weekly serum periostin levels for 12 weeks
in patients who received systemic steroid therapy after
exacerbations. The authors stated that serum periostin
levels varied during this period and 12th-week levels were
higher than baseline levels at admission. The difference
showed a clear tendency to significance [median 3.93
(3.87–4.16) ng/mL vs. 3.89 (3.74–4.2) ng/mL; p = 0.06]
[29]. However, exacerbation etiologies were not included
for comparison in this study. It is of great importance that
this and future studies investigate periostin level changes
according to exacerbation etiologies, even according to
different respiratory tract pathogens.

Viral infections are frequent triggers of asthma
exacerbations. Influenza, coronavirus, parainfluenza,
and most commonly rhinovirus are associated with
exacerbations of asthma in children and adults [30]. It
has been shown that viral infections may interact with
the allergic inflammation in the airways and induce
exacerbations in asthmatic patients. Allergic sensitization
or eosinophilic inflammation further increases the risk
for wheezing illnesses [30]. Following the local epithelial
damage due to viral infection, production of IL-25, IL33, and TSLP increases, which stimulates ILC2s, and as a
result, T2 inflammation is induced. On the other hand, in
non-T2 asthma models, after epithelial injury, IL-6, TNF,
and IL-1a production are stimulated, and neutrophilic
inflammation is induced [12]. There is evidence that IgEmediated allergic inflammation could reduce virus-induced
interferon responses in asthma [30, 31]. In contrast, it was
also shown that type-1 interferons can inhibit Th2 immune
responses [32]. Pritchard et al. showed that IFN-alpha and
IFN-B reduce Th2 cytokine production and interestingly
they also found that when the activity of these interferons
was blocked, IL-13 secretion was increased [32]. The
inhibitory effect of interferons on type 2 cytokine response
has also been shown in other studies. It was shown that
IFN-alpha can markedly inhibit IL-5 production [33].
Type-1 interferons can also block Th2 cytokine secretion
through the inhibition of GATA3 [34]. Supporting these
findings, in our study, during exacerbation periods serum
periostin levels were found significantly lower in patients
with positive viral PCR.
Our study has some limitations. First of all, the total
number of patients and the number of patients in some
phenotypes caused low power for comparisons. Even
though we had similar results, the number of patients
in the exacerbation period and patients with positive
viral PCR were lower than expected. Secondly, we only
performed multiplex PCR in cases with clinical suspicion
of upper respiratory tract infections. This might cause
selection bias. Thirdly, some of the cytokines could not
be detected in the serum. We believe this is unrelated to
a technical error since all tests were performed with the
same brand assays and the same method on the serum
samples that were kept in the same environment. Fourthly,
in order to make a clear distinction between the predefined
phenotypes (particularly phenotypes 2 and 3), we had to
partially move away from real-life and exclude the patients
with peripheral eosinophil count 150–300 cells/mL from
the study. Another possible reason for this is that our
peripheral eosinophil count cut-off value may not be able
to reflect the tissue eosinophilia. Even though peripheral
eosinophil count > 300 cells/mL is a strong predictor of
sputum eosinophilia, and indirectly tissue eosinophilia,
there is still a chance of tissue eosinophilia in the so-called
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noneosinophilic patients who had peripheral eosinophil
count less than 150 eosinophils/mL. Further studies where
eosinophilia is shown in the lower respiratory tract samples
or secretions will enable more accurate results. Lastly, we
studied the serum protein profiles of the phenotypes,
but advanced data analytic approaches such as principal
component analysis or topological data analysis were not
used in contrast to the previous studies.
In conclusion, we showed that IL-13 can be depicted
in the serum of severe asthmatic patients and may reflect
peripheral eosinophilia in patients without systemic steroid
use. In addition, serum periostin levels were increased in
the presence of eosinophilia independent from atopy and

it can help to differentiate eosinophilia even if the patient
is under systemic steroid therapy. Further studies with
larger series, which investigate whether the lower periostin
levels during exacerbations could predict a viral infection
as the underlying etiology and studies on the variations of
periostin levels during exacerbations secondary to viral
infections are needed. Since IL-4, IL-5, IL-10, IL-17, and
IL-33 would not be measured in peripheral blood samples,
we think it is not feasible to use these cytokines in clinical
practice or in the research of the underlying mechanisms of
the asthma phenotypes. We believe our results may shine
a light on severe asthma characterization and personalized
medicine approaches.
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